Detail Information of Exogenous Modulation

General Information of Drug Transporter (DT)
DT ID DTD0006 Transporter Info
Gene Name SLC22A2
Transporter Name Organic cation transporter 2
Gene ID
6582
UniProt ID
O15244
Exogenous factors (drugs, dietary constituents, etc.) Modulation of This DT (EGM)

Approved Drug

  Quinine

            7 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Quinine inhibits the transportation of N-methylpyridinium by SLC22A2 (IC50 = 8.7 microM) [1]

Affected Drug/Substrate

 N-methylpyridinium Modulation Type Inhibition

Cell System

 Oocytes-OCT2

  DT Modulation 2

 Quinine inhibits the transportation of N-methylpyridinium by SLC22A2 (IC50 = 23 microM) [2]

Affected Drug/Substrate

 N-methylpyridinium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-OCT2

  DT Modulation 3

 Quinine inhibits the transportation of N-methylpyridinium by SLC22A2 (IC50 = 13.3 microM) [3]

Affected Drug/Substrate

 N-methylpyridinium Modulation Type Inhibition

Cell System

 Chinese hamster ovary (CHO) cells-OCT2

  DT Modulation 4

 Quinine inhibits the transportation of N-methylpyridinium by SLC22A2 (IC50 = 87 microM) [4]

Affected Drug/Substrate

 N-methylpyridinium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-OCT2

  DT Modulation 5

 Quinine inhibits the transportation of Tetraethylammonium by SLC22A2 (Ki = 3.4 microM) [5]

Affected Drug/Substrate

 Tetraethylammonium Modulation Type Inhibition

Cell System

 Oocytes-OCT2

  DT Modulation 6

 Quinine inhibits the transportation of YM155 by SLC22A2 (IC50 = 11 microM) [6]

Affected Drug/Substrate

 YM155 Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-OCT2

  DT Modulation 7

 Quinine inhibits the activity of SLC22A2 [7]

Cell System

 Xenopus laevis oocytes-OCT2

  Cimetidine

            5 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Cimetidine inhibits the transportation of N-methylpyridinium by SLC22A2 (IC50 = 120 microM) [4]

Affected Drug/Substrate

 N-methylpyridinium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-OCT2

  DT Modulation 2

 Cimetidine inhibits the transportation of Tetraethylammonium by SLC22A2 (IC50 = 373 microM) [8]

Affected Drug/Substrate

 Tetraethylammonium Modulation Type Inhibition

Cell System

 Oocytes-OCT2

  DT Modulation 3

 Cimetidine inhibits the transportation of YM155 by SLC22A2 (IC50 = 110 microM) [6]

Affected Drug/Substrate

 YM155 Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-OCT2

  DT Modulation 4

 Cimetidine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A2 [9]

Affected Drug/Substrate

 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition

  DT Modulation 5

 Cimetidine inhibits the activity of SLC22A2 [10] , [11]

  Ranitidine

            4 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Ranitidine inhibits the transportation of Cimetidine by SLC22A2 (Ki = 79 microM) [12]

Affected Drug/Substrate

 Cimetidine Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-OCT2

  DT Modulation 2

 Ranitidine inhibits the transportation of Famotidine by SLC22A2 (Ki = 30.5 microM) [12]

Affected Drug/Substrate

 Famotidine Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-OCT2

  DT Modulation 3

 Ranitidine inhibits the transportation of N-methylpyridinium by SLC22A2 (IC50 = 76 microM) [1]

Affected Drug/Substrate

 N-methylpyridinium Modulation Type Inhibition

Cell System

 Oocytes-OCT2

  DT Modulation 4

 Ranitidine inhibits the transportation of N-methylpyridinium by SLC22A2 (IC50 = 1617 microM) [2]

Affected Drug/Substrate

 N-methylpyridinium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-OCT2

  Metformin

            4 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Metformin inhibits the transportation of N-methylpyridinium by SLC22A2 (IC50 = 521 microM) [1]

Affected Drug/Substrate

 N-methylpyridinium Modulation Type Inhibition

Cell System

 Oocytes-OCT2

  DT Modulation 2

 Metformin inhibits the transportation of N-methylpyridinium by SLC22A2 (IC50 = 398 microM) [4]

Affected Drug/Substrate

 N-methylpyridinium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-OCT2

  DT Modulation 3

 Metformin inhibits the transportation of N-methylpyridinium by SLC22A2 (Ki = 289 microM) [13]

Affected Drug/Substrate

 N-methylpyridinium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-OCT2

  DT Modulation 4

 Metformin inhibits the transportation of Tetraethylammonium by SLC22A2 (Ki = 1380 microM) [13]

Affected Drug/Substrate

 Tetraethylammonium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-OCT2

  Clonidine

            2 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Clonidine inhibits the transportation of N-methylpyridinium by SLC22A2 (IC50 = 23 microM) [2]

Affected Drug/Substrate

 N-methylpyridinium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-OCT2

  DT Modulation 2

 Clonidine inhibits the transportation of N-methylpyridinium by SLC22A2 (IC50 = 16 microM) [4]

Affected Drug/Substrate

 N-methylpyridinium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-OCT2

  Diphenhydramine

            2 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Diphenhydramine inhibits the transportation of N-methylpyridinium by SLC22A2 (IC50 = 15 microM) [2]

Affected Drug/Substrate

 N-methylpyridinium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-OCT2

  DT Modulation 2

 Diphenhydramine inhibits the transportation of N-methylpyridinium by SLC22A2 (IC50 = 21 microM) [4]

Affected Drug/Substrate

 N-methylpyridinium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-OCT2

  Amantadine

            2 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Amantadine inhibits the transportation of N-methylpyridinium by SLC22A2 (Ki = 28.4 microM) [16]

Affected Drug/Substrate

 N-methylpyridinium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-OCT2

  DT Modulation 2

 Amantadine inhibits the transportation of YM155 by SLC22A2 (IC50 = 45.9 microM) [6]

Affected Drug/Substrate

 YM155 Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-OCT2

  Carvedilol

            2 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Carvedilol inhibits the transportation of N-methylpyridinium by SLC22A2 (IC50 = 63 microM) [4]

Affected Drug/Substrate

 N-methylpyridinium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-OCT2

  DT Modulation 2

 Carvedilol inhibits the activity of SLC22A2 (IC50 = 3.6 microM) [17]

Cell System

 Human embryonic kidney 293 cells (HEK293)-OCT2

  Flurazepam

            2 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Flurazepam inhibits the transportation of N-methylpyridinium by SLC22A2 (IC50 = 60 microM) [4]

Affected Drug/Substrate

 N-methylpyridinium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-OCT2

  DT Modulation 2

 Flurazepam inhibits the activity of SLC22A2 [20]

  Mexiletine

            2 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Mexiletine inhibits the transportation of N-methylpyridinium by SLC22A2 (IC50 = 55 microM) [4]

Affected Drug/Substrate

 N-methylpyridinium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-OCT2

  DT Modulation 2

 Mexiletine inhibits the activity of SLC22A2 [20]

  Propranolol

            2 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Propranolol inhibits the transportation of N-methylpyridinium by SLC22A2 (IC50 = 229 microM) [4]

Affected Drug/Substrate

 N-methylpyridinium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-OCT2

  DT Modulation 2

 Propranolol inhibits the activity of SLC22A2 [20]

  Verapamil

            2 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Verapamil inhibits the transportation of N-methylpyridinium by SLC22A2 (IC50 = 85 microM) [4]

Affected Drug/Substrate

 N-methylpyridinium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-OCT2

  DT Modulation 2

 Verapamil inhibits the transportation of YM155 by SLC22A2 (IC50 = 13.4 microM) [6]

Affected Drug/Substrate

 YM155 Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-OCT2

  Procainamide

            2 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Procainamide inhibits the transportation of Tetraethylammonium by SLC22A2 (Ki = 50 microM) [5]

Affected Drug/Substrate

 Tetraethylammonium Modulation Type Inhibition

Cell System

 Oocytes-OCT2

  DT Modulation 2

 Procainamide inhibits the transportation of YM155 by SLC22A2 (IC50 = 91.9 microM) [6]

Affected Drug/Substrate

 YM155 Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-OCT2

  Telaprevir

            2 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Telaprevir inhibits the activity of SLC22A2 (IC50 = 0.0064 microM) [18]

  DT Modulation 2

 Telaprevir inhibits the activity of SLC22A2 [22]

  Dolutegravir

            2 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Dolutegravir inhibits the transportation of Metformin by SLC22A2 [19]

Affected Drug/Substrate

 Metformin Modulation Type Inhibition

Cell System

 Madin Darby canine kidney strain II (MDCKII) cells-OCT2

  DT Modulation 2

 Dolutegravir inhibits the activity of SLC22A2 [21]

  Estradiol

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Estradiol inhibits the transportation of 1-Methyl-4-phenylpyridinium by SLC22A2 (IC50 > 30 microM) [23]

Affected Drug/Substrate

 1-Methyl-4-phenylpyridinium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-OCT2

  Phenoxybenzamine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Phenoxybenzamine inhibits the transportation of 1-Methyl-4-phenylpyridinium by SLC22A2 (IC50 = 4.9 microM) [23]

Affected Drug/Substrate

 1-Methyl-4-phenylpyridinium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-OCT2

  Progesterone

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Progesterone inhibits the transportation of 1-Methyl-4-phenylpyridinium by SLC22A2 (IC50 = 26.7 microM) [23]

Affected Drug/Substrate

 1-Methyl-4-phenylpyridinium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-OCT2

  Grepafloxacin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Grepafloxacin inhibits the transportation of Creatinine by SLC22A2 (Ki = 10.4 microM) [24]

Affected Drug/Substrate

 Creatinine Modulation Type Inhibition

Cell System

 The Proximal Tubule (S2) Cells-OCT2

  Crizotinib

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Crizotinib inhibits the transportation of Creatinine by SLC22A2 (IC50 = 1.58 +/- 0.24 microM) [25]

Affected Drug/Substrate

 Creatinine Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-OCT2

  Famotidine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Famotidine inhibits the transportation of N-methylpyridinium by SLC22A2 (IC50 = 114 microM) [1]

Affected Drug/Substrate

 N-methylpyridinium Modulation Type Inhibition

Cell System

 Oocytes-OCT2

  Atropine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Atropine inhibits the transportation of N-methylpyridinium by SLC22A2 (IC50 = 39 microM) [2]

Affected Drug/Substrate

 N-methylpyridinium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-OCT2

  Butylscopolamine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Butylscopolamine inhibits the transportation of N-methylpyridinium by SLC22A2 (IC50 = 764 microM) [2]

Affected Drug/Substrate

 N-methylpyridinium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-OCT2

  Cocaine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Cocaine inhibits the transportation of N-methylpyridinium by SLC22A2 (Ki = 113 microM) [16]

Affected Drug/Substrate

 N-methylpyridinium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-OCT2

  Dextroamphetamine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Dextroamphetamine inhibits the transportation of N-methylpyridinium by SLC22A2 (Ki = 10.5 microM) [16]

Affected Drug/Substrate

 N-methylpyridinium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-OCT2

  Ketamine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Ketamine inhibits the transportation of N-methylpyridinium by SLC22A2 (Ki = 22.7 microM) [16]

Affected Drug/Substrate

 N-methylpyridinium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-OCT2

  Memantine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Memantine inhibits the transportation of N-methylpyridinium by SLC22A2 (Ki = 7.3 microM) [16]

Affected Drug/Substrate

 N-methylpyridinium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-OCT2

  Pentamidine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Pentamidine inhibits the transportation of N-methylpyridinium by SLC22A2 (IC50 = 10.6 microM) [3]

Affected Drug/Substrate

 N-methylpyridinium Modulation Type Inhibition

Cell System

 Chinese hamster ovary (CHO) cells-OCT2

  Amitriptyline

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Amitriptyline inhibits the transportation of N-methylpyridinium by SLC22A2 (IC50 = 14 microM) [4]

Affected Drug/Substrate

 N-methylpyridinium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-OCT2

  Chloroquine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Chloroquine inhibits the transportation of N-methylpyridinium by SLC22A2 (IC50 = 1096 microM) [4]

Affected Drug/Substrate

 N-methylpyridinium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-OCT2

  Chlorpromazine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Chlorpromazine inhibits the transportation of N-methylpyridinium by SLC22A2 (IC50 = 14 microM) [4]

Affected Drug/Substrate

 N-methylpyridinium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-OCT2

  Disopyramide

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Disopyramide inhibits the transportation of N-methylpyridinium by SLC22A2 (IC50 = 324 microM) [4]

Affected Drug/Substrate

 N-methylpyridinium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-OCT2

  Doxepin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Doxepin inhibits the transportation of N-methylpyridinium by SLC22A2 (IC50 = 13 microM) [4]

Affected Drug/Substrate

 N-methylpyridinium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-OCT2

  Flecainide

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Flecainide inhibits the transportation of N-methylpyridinium by SLC22A2 (IC50 = 191 microM) [4]

Affected Drug/Substrate

 N-methylpyridinium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-OCT2

  Imipramine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Imipramine inhibits the transportation of N-methylpyridinium by SLC22A2 (IC50 = 6 microM) [4]

Affected Drug/Substrate

 N-methylpyridinium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-OCT2

  Mefloquine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Mefloquine inhibits the transportation of N-methylpyridinium by SLC22A2 (IC50 = 204 microM) [4]

Affected Drug/Substrate

 N-methylpyridinium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-OCT2

  Propafenone

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Propafenone inhibits the transportation of N-methylpyridinium by SLC22A2 (IC50 = 25 microM) [4]

Affected Drug/Substrate

 N-methylpyridinium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-OCT2

  Sibutramine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Sibutramine inhibits the transportation of N-methylpyridinium by SLC22A2 (IC50 = 29 microM) [4]

Affected Drug/Substrate

 N-methylpyridinium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-OCT2

  Tamoxifen

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Tamoxifen inhibits the transportation of N-methylpyridinium by SLC22A2 (IC50 = 87 microM) [4]

Affected Drug/Substrate

 N-methylpyridinium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-OCT2

  Trimethoprim

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Trimethoprim inhibits the transportation of N-methylpyridinium by SLC22A2 (IC50 = 1318 microM) [4]

Affected Drug/Substrate

 N-methylpyridinium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-OCT2

  Decitabine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Decitabine inhibits DNA methyltransferase, which then enhances Oxaliplatin's transportation via downregulating the hypermethylation in SLC22A2's promoter [27]

Affected Drug/Substrate

 Oxaliplatin Modulation Type Inducer

Cell System

 Human renal cell carcinoma cells (RCC)

  Vorinostat

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Vorinostat inhibits histone deacetylase, which then enhances Oxaliplatin's transportation via increasing the histone acethylation level of SLC22A2 (IC50 = 4.69 microM) [28]

Affected Drug/Substrate

 Oxaliplatin Modulation Type Inducer

Cell System

 Human renal cell carcinoma cells (RCC)

  Desipramine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Desipramine inhibits the transportation of Tetraethylammonium by SLC22A2 (IC50 = 16 microM) [5]

Affected Drug/Substrate

 Tetraethylammonium Modulation Type Inhibition

Cell System

 Oocytes-OCT2

  Prazosin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Prazosin inhibits the transportation of YM155 by SLC22A2 (IC50 = 80.4 microM) [6]

Affected Drug/Substrate

 YM155 Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-OCT2

  Testosterone

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Testosterone inhibits the activity of SLC22A2 (IC50 = 3 microM) [33]

  Nicotine polacrilex

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Nicotine inhibits the transportation of Tetraethylammonium by SLC22A2 [34]

Affected Drug/Substrate

 Tetraethylammonium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-OCT2

  Vitamin B1

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Vitamin B1 inhibits the transportation of Tetraethylammonium by SLC22A2 [34]

Affected Drug/Substrate

 Tetraethylammonium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-OCT2

  Cetirizine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Cetirizine inhibits the transportation of Tetraethylammonium by SLC22A2 [35]

Affected Drug/Substrate

 Tetraethylammonium Modulation Type Inhibition

Cell System

 Oocytes-OCT2

  Pilsicainide

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Pilsicainide inhibits the transportation of Tetraethylammonium by SLC22A2 [35]

Affected Drug/Substrate

 Tetraethylammonium Modulation Type Inhibition

Cell System

 Oocytes-OCT2

  Quercetin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Quercetin induces the transportation of Tetraethylammonium by SLC22A2 [36]

Affected Drug/Substrate

 Tetraethylammonium Modulation Type Inhibition

Cell System

 Human enterocyte-like 2 cell (Caco-2); LLC-PK1 vesicles

  Metoprolol

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Metoprolol inhibits the transportation of Cimetidine by SLC22A2 [38]

Affected Drug/Substrate

 Cimetidine Modulation Type Inhibition

  Oxprenolol

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Oxprenolol inhibits the transportation of Cimetidine by SLC22A2 [38]

Affected Drug/Substrate

 Cimetidine Modulation Type Inhibition

  Indomethacin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Indomethacin inhibits the activity of SLC22A2 [39]

  Naproxen

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Naproxen inhibits the activity of SLC22A2 [39]

  Piroxicam

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Piroxicam inhibits the activity of SLC22A2 [39]

  Sulindac

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Sulindac inhibits the activity of SLC22A2 [39]

  Valproic Acid

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Valproic Acid affects the expression of SLC22A2 [40]

  Cisplatin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Cisplatin inhibits the activity of SLC22A2 [41] , [42]

  Dexamethasone

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Dexamethasone induces the activity of SLC22A2 [43]

  Budesonide

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Budesonide inhibits the activity of SLC22A2 [44]

  Plazomicin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Plazomicin inhibits the activity of SLC22A2 [45]

  Vancomycin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Vancomycin inhibits the activity of SLC22A2 [46]

  Itraconazole

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Itraconazole inhibits the activity of SLC22A2 [47]

  Ketoconazole

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Ketoconazole inhibits the activity of SLC22A2 [47]

  Triazolam

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Triazolam inhibits the activity of SLC22A2 [30]

  Diazepam

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Diazepam inhibits the activity of SLC22A2 [30]

  Haloperidol

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Haloperidol inhibits the activity of SLC22A2 [30]

  Lidocaine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Lidocaine inhibits the activity of SLC22A2 [30]

  Malathion

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Malathion inhibits the activity of SLC22A2 [30]

  Mianserin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Mianserin inhibits the activity of SLC22A2 [30]

Drug in Phase 4 Trial

  Pyridine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Pyridine inhibits the transportation of Tetraethylammonium by SLC22A2 (IC50 = 790 microM) [29]

Affected Drug/Substrate

 Tetraethylammonium Modulation Type Inhibition

Cell System

 Chinese hamster ovary (CHO) cells-OCT2

Drug in Phase 2 Trial

  YM155

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 YM155 inhibits the transportation of N-methylpyridinium by SLC22A2 (IC50 = 15.9 microM) [6]

Affected Drug/Substrate

 N-methylpyridinium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-OCT2

  Genistein

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Genistein induces the transportation of Tetraethylammonium by SLC22A2 [36]

Affected Drug/Substrate

 Tetraethylammonium Modulation Type Inhibition

Cell System

 Human enterocyte-like 2 cell (Caco-2); LLC-PK1 vesicles

  MeIQx

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 MeIQx inhibits the activity of SLC22A2 [50]

Drug in Phase 1 Trial

  Naringenin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Naringenin induces the transportation of Tetraethylammonium by SLC22A2 [36]

Affected Drug/Substrate

 Tetraethylammonium Modulation Type Inhibition

Cell System

 Human enterocyte-like 2 cell (Caco-2); LLC-PK1 vesicles

Drug in Preclinical Test

  N-methylpyridinium

            2 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 N-methylpyridinium inhibits the transportation of Tetraethylammonium by SLC22A2 (Ki = 2.4 microM) [5]

Affected Drug/Substrate

 Tetraethylammonium Modulation Type Inhibition

Cell System

 Oocytes-OCT2

  DT Modulation 2

 N-methylpyridinium inhibits the transportation of YM155 by SLC22A2 (IC50 = 4.42 microM) [6]

Affected Drug/Substrate

 YM155 Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-OCT2

  Beta-carboline

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Beta-carboline inhibits the activity of SLC22A2 [50]

Discontinued Drug

  DX-619

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 DX-619 inhibits the transportation of Creatinine by SLC22A2 (Ki = 0.94 microM) [24]

Affected Drug/Substrate

 Creatinine Modulation Type Inhibition

Cell System

 The Proximal Tubule (S2) Cells-OCT2

  Dizocilpine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Dizocilpine inhibits the transportation of N-methylpyridinium by SLC22A2 (Ki = 21.5 microM) [16]

Affected Drug/Substrate

 N-methylpyridinium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-OCT2

  Antiparasitics

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Antiparasitics inhibits the transportation of N-methylpyridinium by SLC22A2 (IC50 = 182 microM) [3]

Affected Drug/Substrate

 N-methylpyridinium Modulation Type Inhibition

Cell System

 Chinese hamster ovary (CHO) cells-OCT2

  Acecainide

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Acecainide inhibits the transportation of Tetraethylammonium by SLC22A2 [34]

Affected Drug/Substrate

 Tetraethylammonium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-OCT2

Investigative Drug

  Tetraethylammonium

            2 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Tetraethylammonium inhibits the transportation of N-methylpyridinium by SLC22A2 (IC50 = 222 microM) [1]

Affected Drug/Substrate

 N-methylpyridinium Modulation Type Inhibition

Cell System

 Oocytes-OCT2

  DT Modulation 2

 Tetraethylammonium inhibits the transportation of N-methylpyridinium by SLC22A2 (IC50 = 189.2 microM) [3]

Affected Drug/Substrate

 N-methylpyridinium Modulation Type Inhibition

Cell System

 Chinese hamster ovary (CHO) cells-OCT2

  Decynium 22

            2 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Decynium 22 inhibits the transportation of Tetraethylammonium by SLC22A2 (IC50 = 13.8 microM) [8]

Affected Drug/Substrate

 Tetraethylammonium Modulation Type Inhibition

Cell System

 Oocytes-OCT2

  DT Modulation 2

 Decynium 22 inhibits the transportation of Tetraethylammonium by SLC22A2 (Ki = 0.1 microM) [5]

Affected Drug/Substrate

 Tetraethylammonium Modulation Type Inhibition

Cell System

 Oocytes-OCT2

  Phencyclidine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Phencyclidine inhibits the transportation of N-methylpyridinium by SLC22A2 (Ki = 24.9 microM) [16]

Affected Drug/Substrate

 N-methylpyridinium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-OCT2

  Corticosterone

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Corticosterone inhibits the transportation of YM155 by SLC22A2 (IC50 = 5.35 microM) [6]

Affected Drug/Substrate

 YM155 Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-OCT2

  Monocrotaline

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Monocrotaline inhibits the activity of SLC22A2 (IC50 = 1800 microM) [53]

Cell System

 Human embryonic kidney 293 cells (HEK293)

Patented Pharmaceutical Agent

  GSK-J4

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 GSK-J4 increases the expression of SLC22A2 [49]

Drug Withdrawn

  Phenformin

            2 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Phenformin inhibits the transportation of N-methylpyridinium by SLC22A2 (Ki = 54 microM) [13]

Affected Drug/Substrate

 N-methylpyridinium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-OCT2

  DT Modulation 2

 Phenformin inhibits the transportation of Tetraethylammonium by SLC22A2 (Ki = 111 microM) [13]

Affected Drug/Substrate

 Tetraethylammonium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-OCT2

  Etilefrine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Etilefrine inhibits the transportation of N-methylpyridinium by SLC22A2 (IC50 = 4009 microM) [2]

Affected Drug/Substrate

 N-methylpyridinium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-OCT2

  Fenfluramine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Fenfluramine inhibits the transportation of N-methylpyridinium by SLC22A2 (IC50 = 10 microM) [4]

Affected Drug/Substrate

 N-methylpyridinium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-OCT2

Natural Product

  Fenamiphos

            2 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Fenamiphos inhibits the transportation of Dopamine by SLC22A2 (IC50 = 2.8 microM) [14]

Affected Drug/Substrate

 Dopamine Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-OCT2

  DT Modulation 2

 Fenamiphos inhibits the transportation of Rhodamine 123 by SLC22A2 (IC50 = 6.9 microM) [14]

Affected Drug/Substrate

 Rhodamine 123 Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-OCT2

  Phosmet

            2 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Phosmet inhibits the transportation of Dopamine by SLC22A2 (IC50 = 3.6 microM) [14]

Affected Drug/Substrate

 Dopamine Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-OCT2

  DT Modulation 2

 Phosmet inhibits the transportation of Rhodamine 123 by SLC22A2 (IC50 = 7.9 microM) [14]

Affected Drug/Substrate

 Rhodamine 123 Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-OCT2

  Piperine

            2 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Piperine inhibits the transportation of Metformin by SLC22A2 (IC50 = 3.727 microM) [15]

Affected Drug/Substrate

 Metformin Modulation Type Inhibition

Cell System

 Madin darby canine kidney strain cell line (MDCK)-OCT2

  DT Modulation 2

 Piperine inhibits the transportation of Serotonin by SLC22A2 (IC50 = 5.4 microM) [15]

Affected Drug/Substrate

 Serotonin Modulation Type Inhibition

Cell System

 Madin darby canine kidney strain cell line (MDCK)-OCT2

  Citreoverdine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Citreoverdine inhibits the transportation of Organic cation by SLC22A2 (IC50 = 17.7 microM) [26]

Affected Drug/Substrate

 Organic cation Modulation Type Inhibition

Cell System

 The Proximal Tubule (S2) Cells-OCT2

  Allethrin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Allethrin inhibits the transportation of Verapamil by SLC22A2 (IC50 = 42.6 microM) [31]

Affected Drug/Substrate

 Verapamil Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-OCT2

  Tetramethrin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Tetramethrin inhibits the transportation of Verapamil by SLC22A2 (IC50 = 11.2 microM) [31]

Affected Drug/Substrate

 Verapamil Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-OCT2

  Cigarette smoke condensate

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Cigarette smoke condensate inhibits the activity of SLC22A2 (IC50 = 12.5 microM) [32]

Cell System

 Human embryonic kidney 293 cells (HEK293)-OCT2

  Green tea

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Green tea inhibits the transportation of Metformin by SLC22A2 [37]

Affected Drug/Substrate

 Metformin Modulation Type Inhibition

Cell System

 Human enterocyte-like 2 cell (Caco-2)-OCT2

  Tobacco Smoke Pollution

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Tobacco Smoke Pollution inhibits the activity of SLC22A2 [32]

  Chlorpyrifos

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Chlorpyrifos inhibits the activity of SLC22A2 [30]

  Rhein

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Rhein up-regulated the expressions of SLC22A2 [54]

Cell System

 NRK-52E cells

Biotoxin

  Aconitine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Aconitine inhibits the transportation of Tetraethylammonium by SLC22A2 (IC50 = 59.2 microM) [30]

Affected Drug/Substrate

 Tetraethylammonium Modulation Type Inhibition

Cell System

 The Proximal Tubule (S2) Cells-OCT2

Environmental toxicant

  Fenitrothion

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Fenitrothion inhibits the activity of SLC22A2 [30]

Mycotoxins

  Aflatoxin B1

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Aflatoxin B1 inhibits the transportation of Organic cation by SLC22A2 (IC50 = 121 microM) [26]

Affected Drug/Substrate

 Organic cation Modulation Type Inhibition

Cell System

 The Proximal Tubule (S2) Cells-OCT2

  Alpha-zearalenol

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Alpha-zearalenol inhibits the transportation of Organic cation by SLC22A2 (IC50 = 34.3 microM) [26]

Affected Drug/Substrate

 Organic cation Modulation Type Inhibition

Cell System

 The Proximal Tubule (S2) Cells-OCT2

  Citrioveridine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Citrioveridine inhibits the transportation of Organic cation by SLC22A2 (IC50 = 17.7 microM) [26]

Affected Drug/Substrate

 Organic cation Modulation Type Inhibition

Cell System

 The Proximal Tubule (S2) Cells-OCT2

  Cyclopiazonic acid

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Cyclopiazonic acid inhibits the transportation of Organic cation by SLC22A2 (IC50 > 1000 microM) [26]

Affected Drug/Substrate

 Organic cation Modulation Type Inhibition

Cell System

 The Proximal Tubule (S2) Cells-OCT2

  Fumonisin B1

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Fumonisin B1 inhibits the transportation of Organic cation by SLC22A2 [26]

Affected Drug/Substrate

 Organic cation Modulation Type Inhibition

Cell System

 The Proximal Tubule (S2) Cells-OCT2

  Patulin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Patulin inhibits the transportation of Organic cation by SLC22A2 (IC50 > 1000 microM) [26]

Affected Drug/Substrate

 Organic cation Modulation Type Inhibition

Cell System

 The Proximal Tubule (S2) Cells-OCT2

  Gliotoxin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Gliotoxin inhibits the transportation of Organic cation by SLC22A2 (IC50 = 117 microM) [26]

Affected Drug/Substrate

 Organic cation Modulation Type Inhibition

Cell System

 The Proximal Tubule (S2) Cells-OCT2

  Zearalenone

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Zearalenone inhibits the transportation of Organic cation by SLC22A2 (IC50 = 24.8 microM) [26]

Affected Drug/Substrate

 Organic cation Modulation Type Inhibition

Cell System

 The Proximal Tubule (S2) Cells-OCT2

Acute Toxic Substance

  Mercuric Chloride

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Mercuric Chloride inhibits the activity of SLC22A2 [48]

  2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine inhibits the activity of SLC22A2 [50]

Carcinogen

  2-amino-3-methylimidazo(4,5-f)quinoline

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 2-amino-3-methylimidazo(4,5-f)quinoline inhibits the activity of SLC22A2 [50]

  Benzo(a)pyrene

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Benzo(a)pyrene inhibits the expression of SLC22A2 [52]

Pesticide/Insecticide

  Clothianidin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Clothianidin inhibits the activity of SLC22A2 [51]

  Imidacloprid

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Imidacloprid inhibits the activity of SLC22A2 [51]

  Thiamethoxam

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Thiamethoxam inhibits the activity of SLC22A2 [51]
References
1 Differential substrate and inhibitory activities of ranitidine and famotidine toward human organic cation transporter 1 (hOCT1; SLC22A1), hOCT2 (SLC22A2), and hOCT3 (SLC22A3). J Pharmacol Exp Ther. 2005 Dec;315(3):1288-97.
2 Drug specificity and intestinal membrane localization of human organic cation transporters (OCT). Biochem Pharmacol. 2005 Dec 5;70(12):1851-60.
3 Transport of dicationic drugs pentamidine and furamidine by human organic cation transporters. Drug Metab Dispos. 2009 Feb;37(2):424-30.
4 Structural determinants of inhibitor interaction with the human organic cation transporter OCT2 (SLC22A2). Naunyn Schmiedebergs Arch Pharmacol. 2009 Apr;379(4):337-48.
5 Cloning and characterization of two human polyspecific organic cation transporters. DNA Cell Biol. 1997 Jul;16(7):871-81.
6 Characterization of human organic cation transporter 1 (OCT1/SLC22A1)- and OCT2 (SLC22A2)-mediated transport of 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)- 4,9-dihydro-1H-naphtho[2,3-d]imidazolium bromide (YM155 monobromide), a novel small molecule survivin suppressant. Drug Metab Dispos. 2010 Jan;38(1):1-4.
7 Ventricular choline transport: a role for organic cation transporter 2 expressed in choroid plexus. J Biol Chem. 2001 Nov 9;276(45):41611-9.
8 Molecular mechanisms of organic cation transport in OCT2-expressing Xenopus oocytes. Biochim Biophys Acta. 1999 Mar 4;1417(2):224-31.
9 Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2. J Med Chem. 2011 Jul 14;54(13):4548-58.
10 Elevated systemic elimination of cimetidine in rats with acute biliary obstruction: the role of renal organic cation transporter OCT2. Drug Metab Pharmacokinet. 2010;25(4):328-34.
11 The human organic cation transporter (hOCT2) recognizes the degree of substrate ionization. J Biol Chem. 2002 Jun 21;277(25):22491-6.
12 A species difference in the transport activities of H2 receptor antagonists by rat and human renal organic anion and cation transporters. J Pharmacol Exp Ther. 2005 Oct;315(1):337-45.
13 Comparison of the kinetic characteristics of inhibitory effects exerted by biguanides and H2-blockers on human and rat organic cation transporter-mediated transport: Insight into the development of drug candidates. Xenobiotica. 2007 Jun;37(6):618-34.
14 Interactions of organophosphorus pesticides with solute carrier (SLC) drug transporters. Xenobiotica. 2019 Mar;49(3):363-374.
15 Involvement of organic cation transporter 2 inhibition in potential mechanisms of antidepressant action. Prog Neuropsychopharmacol Biol Psychiatry. 2014 Aug 4;53:90-8.
16 Differential pharmacological in vitro properties of organic cation transporters and regional distribution in rat brain. Neuropharmacology. 2006 Jun;50(8):941-52.
17 Selective Inhibition on Organic Cation Transporters by Carvedilol Protects Mice from Cisplatin-Induced Nephrotoxicity. Pharm Res. 2018 Sep 6;35(11):204.
18 Drug interactions and protease inhibitors used in the treatment of hepatitis C: how to manage? Eur J Clin Pharmacol. 2014 Jul;70(7):775-89.
19 In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor. Drug Metab Dispos. 2013 Feb;41(2):353-61.
20 Functional characterization of the human organic cation transporter 2 variant p.270Ala>Ser. Drug Metab Dispos. 2009 Jun;37(6):1312-8.
21 Raltegravir has a low propensity to cause clinical drug interactions through inhibition of major drug transporters: an in vitro evaluation. Antimicrob Agents Chemother. 2014;58(3):1294-301.
22 eGFR decrease during antiviral C therapy with first generation protease inhibitors: a clinical significance? Liver Int. 2015 Jan;35(1):71-8.
23 Expression and pharmacological profile of the human organic cation transporters hOCT1, hOCT2 and hOCT3. Br J Pharmacol. 2002 Jul;136(6):829-36.
24 Prediction of fluoroquinolone-induced elevation in serum creatinine levels: a case of drug-endogenous substance interaction involving the inhibition of renal secretion. Clin Pharmacol Ther. 2011 Jan;89(1):81-8.
25 Inhibitory Effect of Crizotinib on Creatinine Uptake by Renal Secretory Transporter OCT2. J Pharm Sci. 2017 Sep;106(9):2899-2903.
26 Interactions of organic anion transporters and organic cation transporters with mycotoxins. J Pharmacol Sci. 2008 Mar;106(3):435-43.
27 Epigenetic activation of the drug transporter OCT2 sensitizes renal cell carcinoma to oxaliplatin. Sci Transl Med. 2016 Jul 20;8(348):348ra97.
28 Regulation of OCT2 transcriptional repression by histone acetylation in renal cell carcinoma. Epigenetics. 2019 May 15:1-13.
29 Characterization of the inhibitory effects of N-butylpyridinium chloride and structurally related ionic liquids on organic cation transporters 1/2 and human toxic extrusion transporters 1/2-k in vitro and in vivo. Drug Metab Dispos. 2011 Sep;39(9):1755-61.
30 Human organic cation transporter 2 (hOCT2): Inhibitor studies using S2-hOCT2 cells. Toxicology. 2013 Aug 9;310:98-103.
31 Inhibition of Human Drug Transporter Activities by the Pyrethroid Pesticides Allethrin and Tetramethrin. PLoS One. 2017 Jan 18;12(1):e0169480.
32 Inhibition of organic anion transporter (OAT) activity by cigarette smoke condensate. Toxicol In Vitro. 2017 Oct;44:27-35.
33 Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications. Pharm Res. 2007 Jul;24(7):1227-51.
34 cDNA cloning, functional characterization, and tissue distribution of an alternatively spliced variant of organic cation transporter hOCT2 predominantly expressed in the human kidney. J Am Soc Nephrol. 2002 Jul;13(7):1703-10.
35 Severe arrhythmia as a result of the interaction of cetirizine and pilsicainide in a patient with renal insufficiency: first case presentation showing competition for excretion via renal multidrug resistance protein 1 and organic cation transporter 2. Clin Pharmacol Ther. 2006 Apr;79(4):389-96.
36 Effects of dietary flavonoids on the transport of cimetidine via P-glycoprotein and cationic transporters in Caco-2 and LLC-PK1 cell models. Xenobiotica. 2008 Dec;38(12):1536-50.
37 Inhibitory Effects of Green Tea and (-)-Epigallocatechin Gallate on Transport by OATP1B1, OATP1B3, OCT1, OCT2, MATE1, MATE2-K and P-Glycoprotein. PLoS One. 2015 Oct 1;10(10):e0139370.
38 The organic cation transporter OCT2 mediates the uptake of beta-adrenoceptor antagonists across the apical membrane of renal LLC-PK(1) cell monolayers. Br J Pharmacol. 2000 Sep;131(1):71-9.
39 Interactions of human organic anion transporters and human organic cation transporters with nonsteroidal anti-inflammatory drugs. J Pharmacol Exp Ther. 2002 Nov;303(2):534-9.
40 Gene Expression Regulation and Pathway Analysis After Valproic Acid and Carbamazepine Exposure in a Human Embryonic Stem Cell-Based Neurodevelopmental Toxicity Assay. Toxicol Sci. 2015 Aug;146(2):311-20.
41 Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2. Am J Pathol. 2005 Dec;167(6):1477-84.
42 Organic cation transporter OCT/SLC22A and H(+)/organic cation antiporter MATE/SLC47A are key molecules for nephrotoxicity of platinum agents. Biochem Pharmacol. 2011 Mar 1;81(5):563-8.
43 Functional characteristics and steroid hormone-mediated regulation of an organic cation transporter in Madin-Darby canine kidney cells. J Pharmacol Exp Ther. 2001 Oct;299(1):392-8.
44 Polyspecific cation transporters mediate luminal release of acetylcholine from bronchial epithelium. Am J Respir Cell Mol Biol. 2005 Jul;33(1):79-88.
45 No Effect of Plazomicin on the Pharmacokinetics of Metformin in Healthy Subjects. Clin Pharmacol Drug Dev. 2019 Jan 3.
46 JBP485 attenuates vancomycin-induced nephrotoxicity by regulating the expressions of organic anion transporter (Oat) 1, Oat3, organic cation transporter 2 (Oct2), multidrug resistance-associated protein 2 (Mrp2) and P-glycoprotein (P-gp) in rats. Toxicol Lett. 2018 Oct 1;295:195-204.
47 Evaluation of Ketoconazole and Its Alternative Clinical CYP3A4/5 Inhibitors as Inhibitors of Drug Transporters: The In Vitro Effects of Ketoconazole, Ritonavir, Clarithromycin, and Itraconazole on 13 Clinically-Relevant Drug Transporters. Drug Metab Dispos. 2016 Mar;44(3):453-9.
48 Inorganic mercury interacts with cysteine residues (C451 and C474) of hOCT2 to reduce its transport activity. Am J Physiol Renal Physiol. 2007 May;292(5):F1583-91.
49 Inhibition of histone H3K27 demethylases selectively modulates inflammatory phenotypes of natural killer cells. J Biol Chem. 2018 Feb 16;293(7):2422-2437.
50 Inhibition of organic cation transporter (OCT) activities by carcinogenic heterocyclic aromatic amines. Toxicol In Vitro. 2019 Feb;54:10-22.
51 Neonicotinoid pesticides poorly interact with human drug transporters. J Biochem Mol Toxicol. 2019 Oct;33(10):e22379.
52 Identification of a transcriptomic signature of food-relevant genotoxins in human HepaRG hepatocarcinoma cells. Food Chem Toxicol. 2020 Jun;140:111297.
53 An in vitro study on interaction of anisodine and monocrotaline with organic cation transporters of the SLC22 and SLC47 families. Chin J Nat Med. 2019 Jul;17(7):490-497.
54 Protective effect of Rhein against vancomycin-induced nephrotoxicity through regulating renal transporters and Nrf2 pathway. Phytother Res. 2022 Nov;36(11):4244-4262.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.